Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial
Year: 2026
Type: article
Abstract: Importance: The PANOVA-3 trial demonstrated the survival benefit and tolerability of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel, but understanding the impact of TTFields therapy on quality of life (QoL) and pain is important for clinical decision-making. Objective: To analyze the impact of TTFields therapy concomitant with gemcitabine and nab-paclitaxel on QoL and pain outcomes using prospective data from PANOVA-3. Design, Setting, and Participants: This is a prespecified secondary analysis of PANOVA-3, which was a global, open-label, multicenter, phase 3 randomized clinical trial in adult patients with previously untreated locally advanced unresectable pancreatic adenocarcinoma (LA-PAC). A total of 571 patients were randomized between May 1, 2018, and March 31, 2023, with follow-up completed October 31, 2024. Data analysis was performed from November 2024 to May 2025. Intervention: Patients were randomized 1:1 to receive either TTFields therapy (150 kHz) with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously on days 1, 8, and 15 of 28-day cycles. Duration of follow-up was 18 months. Main Outcomes and Measures: QoL was measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire and the 26-item pancreatic cancer module. End points were mean changes from baseline QoL scores, deterioration-free survival of QoL, and time to opioid use. An analysis of pain medication use was performed post hoc. Results: At baseline, 562 patients (median [IQR] age, 67 [31-90] years; 295 [52.5%] female), including 279 of 285 patients in the TTFields plus gemcitabine and nab-paclitaxel arm and 283 of 286 patients in the gemcitabine and nab-paclitaxel arm, completed the EORTC QLQ-C30 questionnaire. Global health status was stable during the 26-month follow-up in both study arms. Digestive symptoms, pain, and pancreatic pain were improved from 2 months after treatment initiation throughout treatment and follow-up in the TTFields plus gemcitabine and nab-paclitaxel arm. TTFields plus gemcitabine and nab-paclitaxel was associated with longer deterioration-free survival for global health status than gemcitabine and nab-paclitaxel alone (median [IQR], 7.1 [3.5-14.8] vs 5.7 [2.3-11.5] months; hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .02). Longer deterioration-free survival was also observed for most items on the digestive symptoms scales (indigestion and altered bowel habit were similar between the 2 arms). Median (IQR) deterioration-free survival was significantly longer with TTFields plus gemcitabine and nab-paclitaxel for pain (10.1 [4.0-20.9] vs 7.4 [3.5-14.5] months; HR, 0.70; 95% CI, 0.54-0.89; P = .003) and pancreatic pain (14.7 [6.2-46.2] vs 10.2 [5.6-18.2] months; HR, 0.69; 95% CI, 0.52-0.90; P = .006) as was median time to opioid use in the modified intention-to-treat population (9.3 [3.9-18.6] vs 6.7 [1.1-16.3] months; HR, 0.72; 95% CI, 0.55-0.93; P = .01). Conclusions and Relevance: This secondary analysis of a randomized clinical trial found that TTFields therapy with gemcitabine and nab-paclitaxel improved QoL and provided clinically meaningful benefits in pain outcomes compared with gemcitabine and nab-paclitaxel alone. This study's results suggest that TTFields therapy with gemicitabine and nab-paclitaxel is practice-changing for patients with unresectable LA-PAC. Trial Registration: ClinicalTrials.gov Identifier: NCT03377491.
Source: JAMA Network Open
Authors: Teresa Macarulla, Vincent Picozzi, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Christelle de la Fouchardière, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip A. Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Hani Babiker, PANOVA-3 study investigators, David Spigel, Joanna Bendell, Arsen Osipov, Andrew Hendifar, Marc Matrana, Nicholas Blondin, Emil Lou, Rachna Shroff, Hani Babiker, Douglas Orr, Carlos Becerra, Michael Anderson, Fadi Braiteh, Anthony Shields, Philip Philip, John Hamm, Andrea Bullock, Mary Peters, Benjamin Schlechter, Sumana Nagireddy, Joanna Kolodney, Tomislav Dragovich, Andrew Coveler, Ajit Maniam, Vincent Picozzi, Judith Sears, Joseph Stilwill, Peter Van Veldhuizen, Jaswinder Singh, Francis Arena, Mike Cusnir, Anna Niewiaroska, William Small, Anup Kasi, Jason Tache, Sharona Ross, Alexander Rosemurgy, Samer Shihabi, Sunil Gandhi, James Reeves, Garrett Green, Trevor Feinstein, Timothy Huyck, Nadia Ramdin, Anand Mahadevan, Robert Marsh, Marisa Hill, Yixing Jiang, Hassan Hatoum, Sudhir Manda, Mark Kochenderfer, Henrik Illum, Donald Richards, Panagiotis Valilis, Lucas Wong, Sreenivasa Chandana, Herbert Newton, Maen Abdelrahim, David Einspahr, Richard Siegel, Scott McKenney, Mohit Narang, Marc Uemura, Higinia Cardenes, Steven DiBiase, Kannan Thanikachalam, John Russell, Joshua Raff, Joseph Ye, Deepti Behl, Audrey Kam, Ashiq Masood, Paul DeRose, Ali Tasneem, Venu Bathini, Warren Brenner, Jennifer De Los Santos, James Wang, Daniel Rausch, Gaurav Trikha, David Park, Nashat Gabrail, Rex Mowat, Khawaja Jahangir, Robert Schumaker, Edward Soffen, Eric Bravin, Mukul Gupta, Ivan Bedoya-Apraez, Tyler Kang, Frederic Lemay, Mark Vincent, Richard Letourneau, Martin Fuchs, Thomas Theodor Werner Seufferlein, Christine Doehring, Jorn Russel, Mike Haberkorn, Arndt Vogel, Karen Russwurm, Jack Chater, Marc Küng, Sabine Schacher, Maria Passhak, Valeriya Semenisty, Ravit Geva, Ayala Hubert, Salomon Stemmer, Talia Golan, Hélène Senellart, Isabelle Trouilloud, Christelle de la Fouchardière, Pauline Rochefort, Jean-Frederic Blan, Luis-Marie Dourthe, Florence Le Roy, Marie Clemence Daniel, Joelle Egreteau, Jérôme Martin-Babau, Meher Ben Abdelghani, Richard Greil, Georg Schreil, Armin Gerger, Wolfgang Eisterer, Teresa Macarulla Mercadé, Antonio Cubillo, Francesc Valladares Pons, Carmen Guillen Ponce, Inmaculada Ales Diaz, Manuel Benavides Orgaz, Fernando Rivera, Javier Gallego Plazas, Ricardo Yaya, Mariano Ponz Sarvise, Bruno Vincenzi, Mario Airoldi, Giovanna Bellotti, Domenico Cristiano Corsi, Lorenzo Antonuzzo, Bohuslav Melichar, Petra Holeckova, Lubos Petruzelka, Rostislav Kotasek, Radim Nemecek, Eric van Cutsem, Jean-Luc van Laethem, Ivan Borbath, Jun Eul Hwang, Sung Yong Oh, Sun Jin Sym, Moon Hee Lee, Jin Young Kim, Sang Cheul Oh, Woo Jin Lee, Joon Oh Park, Jin Won Kim, Myung Ah Lee, Hye Jin Choi, Seok Yun Kang, Hong Jae Chon, Lucjan Wyrwicz, Rodryg Ramlau, Andrzej Mruk, Beata Freier, Ewa Kosakowska, Judit Kocsis, Tibor Csoszi, Erika Hitre, Yousuf Al-Farhat, Ali Bassam, Chunyi Hao, Bo Liang, Shundong Cang, Gang Jin, Changzeng Zuo, Lijie Song, Zheng Wu, Jie Gao, Tao Zhang, Yusheng Wang, Xianglin Yuan, Zhihua Li, Rufu Chen, Wei Li, Xiujun Cai, Zhizhen Zhu, Yuxian Bai, Chunmei Bai, Thomas Yau, Warren Joubert, Ka Yeung Mark Wong, Gavin Marx, Kynan Feeney, Marion Harris, Ana Misir, Zoran Rakusic, Adilson Faccio, Felipe Cruz, Sergio De Azevedo, Ana Paula De Souza Victorino, Tadeu Ferreira de Paiva, Fabio Andre Franke, Katsuki Arima Tiscoski, Gabriel Parolla, Flora Lilno, Mariana Bruno Siqueira, Marcos Lyra, Paulo Hoff, Jose Luis Martinez Lira, Dolores Mendoza Oliva, Arturo Vazquez, Jesus Elvis Cabrera Luviano, Erika Castillo Gutierrez, Vanessa Rosas Camargo, Cristian Chavez Guerra, Osvaldo Hernandez Flores, David Orta Cortez, Saul Campos, Ivan Romarico González Espinoza, Jessica Reyes Contreras, Angel Gomez Villanueva, Omar Zayas Villanueva
Institutions: Hospital Clínic de Barcelona, Virginia Mason Medical Center, University Hospital Olomouc, Palacký University Olomouc, University of Kansas Medical Center, Changhai Hospital, Hospital General Universitario de Elche, Centre Léon Bérard, Beth Israel Deaconess Medical Center, Harvard University, Peking University Cancer Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Cedars-Sinai Medical Center, Baptist MD Anderson Cancer Center, National Cancer Center, St John of God Murdoch Hospital, Wayne State University, Henry Ford Hospital, Kanagawa Cancer Center, KU Leuven, University Hospital Ulm, Mayo Clinic in Florida
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W7225995436
